Cleveland Research

Cleveland Research analyst Michael Piken downgraded Tyson Foods (NYSE: TSN) from Buy to Neutral and lowered the price target from $35 to $30. Piken lowered his rating and price target due to weaker expectations for beef processing. Cleveland Research lowered the outlook across all of Tyson's...

Cleveland Research reported that Nokia (NYSE: NOK) network solutions have lost shares with several European operators as Alcatel gains ground. The analyst commented that Nokia's LTE awards in China are likely to break even or have a slight headwind in profitability. Cleveland Research rates ADR's...

Cleveland Research analyst Eric Bosshard lowered estimates for The Home Depot, Inc. (NYSE: HD) and Lowe's Companies Inc. (NYSE: LOW). Bosshard noted that the softer sales growth is mainly "unit/ traffic driven". The analyst cut Home Depot's Q3 comp sales estimate from 7% to 6.5% and Q4 estimates...

On Thursday, Cleveland Research Company's analyst Kevin Rottinghaus published a report on his research on semiconductors, with a focus on Hynix, Micron (NASDAQ: MU), and SanDisk (NASDAQ: SNDK). A fire at Hynix's facility will continue to increase PC DRAM contract prices to possibly $35-38....

In a report published Thursday, Cleveland Research analyst Jason Whitmer reported that Starbucks Corp. (NASDAQ: SBUX) has a FY14 estimated of $2.72 versus consensus of $2.66 with upside potential to $3. Cleveland Research noted that Americas comps are likely in line with consensus expectations....

In a report published Thursday, Cleveland Research analyst Jeff Stinson decreased Macy's Inc. (NYSE: M) F3Q earnings from $0.42 to $0.40 and modeled M 3Q13 comps to 2% versus consensus of 2.9% due to disappointing present and expected future sales. Stinson noted the company's “inconsistent...

Best 1) Caliper Life Sciences (NASDAQ: CALP): Shares of Caliper Life Sciences are currently trading up 41% from yesterday's close to $10.41. The company will be acquired by PerkinElmer (NYSE: PKI) for $10.50 per share. The deal is valued at $600 million. 2) Achillion Pharmaceuticals (NASDAQ:...